Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01997333
Title Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Acronym METRIC
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS


No variant requirements are available.